Takeda to Discontinue GAMMAGARD S/D by End of 2027 in Strategic Portfolio Realignment
Takeda Pharmaceutical has announced the discontinuation of GAMMAGARD S/D, its legacy immunoglobulin therapy, effective December 2027. The move signals a broader portfolio restructuring as the Japanese pharma giant shifts resources toward higher-margin biologics and specialty medicines. Remaining inventory will continue to be available after the cutoff date until supplies are depleted or expire.
ViaNews Editorial Team (Finance)•